Apr
16
2020
On demand
Lentiviral vector process to accelerate cell and gene therapy clinical development and commercialization
Thursday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST
Sponsor
The burgeoning cellular immunotherapy sector, spearheaded by the approvals of Kymriah and Yescarta, has seen demand for viral vectors increase dramatically year over year. Robust, highly scalable, and predictive lentiviral vector production platforms are a must to enable the cell and gene therapy industry to deliver cost-effective, consistently high-quality products to an ever-growing number of patients.
In this webinar, Miltenyi Biotec present state-of-the-art lentiviral vector production capabilities to support all phases of clinical and commercial manufacturing.
Attendees learn about:
- Enhancing predictability with lentiviral vector production platforms
- Use of serum-free suspension for large-scale lentiviral vector production
- The importance of robust and reproducible results in commercial viral vector production
- Streamlining project timelines while expediting the clinical phase and moving rapidly to the commercial phase
- Ensuring effective process validation to support commercialization of cell therapies
[#speakersPlaceHolder]
SPEAKERS
You might also like
Accelerate the scale-up to clinical phase: optimizing stem cell culture performance and viral vector titers
Sara Bursomanno
24 April
Watch
Innovative approaches to lentiviral vector purification: achieving high yields and purity with a chromatography-free process
Nikki Votaw
20 August
Watch
Think ahead: preparing for challenges to accelerate your cell therapy commercialization
S Ghassemi, S Carmichael, K Henckels et al.
15 May
Watch
How to use AI and machine learning in cell therapy process development
Alex Sargent
13 November
Watch
From concept to clinic: overcoming the challenges of potency assays in cell and gene therapy development
Audrey Chang, Joe Newcome
10 December
in 14
Days